These findings revealed that the GSK3β regulatory lncRNAs can be considered as novel therapeutic targets for better management of RCC (Yang et al., 2018[66]; Ding et al., 2020[8]; Zhang et al., 2021[75]). Here, GSK3B is linked to renal cell carcinoma.